The Sarcoma Group of Spain Shall Head a European Consortium for Evaluating the Lixte Biotechnology Holdings’ LB-100 Ability for Improving First Line Therapy

The Sarcoma Group of Spain Shall Head a European Consortium for Evaluating the Lixte Biotechnology Holdings’ LB-100 Ability for Improving First Line Therapy

Lixte Biotechnology Holdings, Inc. have announced that it has signed an agreement of clinical trial with the Spanish Sarcoma Group for supporting a study of the doxorubicin of Phase 1b/randomized Phase 2 which is the global standard for the basic treatment of the advanced soft tissue sarcomas (ASTS), against the doxorubicin plus LB-100.

The Chief Executive Officer, Dr. John S. Kovach, of Lixte has said that they were pleased to be supporting the trial initiated by the investigator that was proposed by GEIS which has been a leader for several years in trying to improve the therapies for ASTS. GEIS had a network of some referral centers in Spain as well as across Europe that had an amazing track record of professionally conducting the innovative studies in ASTS. He further said that they believed GEIS along with their EU collaborators were an amazing team for evaluating the potential benefit of combining the non-cytotoxic inhibitor of the DNA damage repair of Lixte to the general treatment for this difficult disease. The goal was to enter the 1st patient in the last six months of the current year and for completion of the enrollment of almost 170 patients in the last two years.

Dr. Kovach further said that the Doxorubicin alone had been the mainstay of the first line treatment for ASTS for more than forty years with very little therapeutic gain from the addition of cytotoxic compounds to or the substitution of other compounds that were cytotoxic for doxorubicin.